Imaging with two different methods - fluorescence and MRI. Molecular imaging agents may be useful in bimodal imaging.

Molecular imaging agents may be useful in bimodal imaging - fluorescence and MRI. Bimodal imaging of PBR expressing cells has been possible with Ln-PK-11195, a new imaging agent for the further study of mitochondrial function and its relationship to cancer cell proliferation. By preparing cocktails of both the Gd3+ and Eu3+ or Tb3+ complexes, it will be possible to obtain non-invasive anatomic-scale images by MRI and perform microscopic-scale imaging by fluorescence on the same cell or tissue.
New agents will be created, these include a long circulating bimetallic with enhanced relaxivity for MRI. In-vitro and in-vivo studies will show the safety and efficacy of these molecular imaging agents.

Texas-based university research group. Current projects include: 'Multi-Modal Molecular Imaging Agents' or 'Micro-Fluidics and Nanosensing'. For example, the research group is evaluating Ln-PK-11195 as a bimodal imaging contrast agent for brain cancer detection by MRI and fluorescence.
Please see their Current Projects Abstracts for complete coverage.

Molecular Imaging is a new diagnostic discipline to visualize biological processes.
Molecular magnetic resonance imaging (mMRI) offers the potential to image tissues at the cellular and subcellular level. Targeted MR contrast agents enhance the diagnostic specificity and range of molecular magnetic resonance imaging.
Other modalities that can be used for noninvasive molecular imaging:

See also Nanoparticle, Monocrystalline Iron Oxide Nanoparticle, Polycrystalline Iron Oxide Nanoparticles, Liposomes, Monoclonal Antibodies, Bimodal Imaging, Tumor Specific Agents, and Intracellular Contrast Agents.